Literature DB >> 10933805

R-domain interactions with distal regions of CFTR lead to phosphorylation and activation.

S A King1, E J Sorscher.   

Abstract

Cystic fibrosis is caused by the aberrant function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. We examined whether intramolecular binding interactions involving the regulatory (R) domain contributed to CFTR regulation and function. When the R-domain (amino acids 596-836) was coexpressed with Delta1-836 CFTR (a carboxyl hemi-CFTR beginning immediately after the R-domain), strong binding between the two polypeptides was exhibited. The R-domain that co-immunoprecipitated with Delta1-836 exhibited a slower mobility on SDS-PAGE that resulted from phosphorylation of the protein. A larger CFTR polypeptide that included the R-domain (M837X) also exhibited a phosphorylation-dependent mobility shift when coexpressed with Delta1-836. Moreover, coexpression of M837X and Delta1-836 led to enhanced halide permeability in living cells. The activity, unlike in full-length CFTR, was present without forskolin activation, but still sensitive to the PKA inhibitor, Rp-8-CPT-cAMPS. This PKA inhibition of activity was found to be dependent on the carboxy region of the R-domain, amino acids 723-836. Our results indicate that the R-domain binds CFTR residues after amino acid 836 and that this binding facilitates phosphorylation and CFTR activation. We have also characterized a subdomain within CFTR (residues 723-837) that is necessary for PKA-dependent constitutive activation. Finally, these experiments demonstrate that constitutive CFTR activity can be accomplished by at least two mechanisms: (1) direct modulation of the R-domain to abrogate PKA regulation and (2) modifications that increase R-domain susceptibility to steady-state phosphorylation through PKA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933805     DOI: 10.1021/bi992807d

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Phosphorylation of CFTR by PKA promotes binding of the regulatory domain.

Authors:  Valerie Chappe; Thomas Irvine; Jie Liao; Alexandra Evagelidis; John W Hanrahan
Journal:  EMBO J       Date:  2005-07-07       Impact factor: 11.598

2.  Negative regulation of the yeast ABC transporter Ycf1p by phosphorylation within its N-terminal extension.

Authors:  Christian M Paumi; Matthew Chuk; Igor Chevelev; Igor Stagljar; Susan Michaelis
Journal:  J Biol Chem       Date:  2008-07-29       Impact factor: 5.157

3.  Protein kinase A regulates ATP hydrolysis and dimerization by a CFTR (cystic fibrosis transmembrane conductance regulator) domain.

Authors:  L Daniel Howell; Roy Borchardt; Jolanta Kole; Andrew M Kaz; Christoph Randak; Jonathan A Cohn
Journal:  Biochem J       Date:  2004-02-15       Impact factor: 3.857

4.  S-palmitoylation regulates biogenesis of core glycosylated wild-type and F508del CFTR in a post-ER compartment.

Authors:  Michelle L McClure; Hui Wen; James Fortenberry; Jeong S Hong; Eric J Sorscher
Journal:  Biochem J       Date:  2014-04-15       Impact factor: 3.857

5.  The CFTR P67L variant reveals a key role for N-terminal lasso helices in channel folding, maturation, and pharmacologic rescue.

Authors:  Carleen Mae Sabusap; Disha Joshi; Luba Simhaev; Kathryn E Oliver; Hanoch Senderowitz; Marcel van Willigen; Ineke Braakman; Andras Rab; Eric J Sorscher; Jeong S Hong
Journal:  J Biol Chem       Date:  2021-03-26       Impact factor: 5.486

6.  Membrane transplantation to correct integral membrane protein defects.

Authors:  Kimberly V Curlee; Jeong S Hong; J P Clancy; Scott A King; Eric Hunter; Bakhrom Berdiev; Dale Benos; Maja A Sommerfelt; Eric J Sorscher; Michael Sakalian
Journal:  J Mol Med (Berl)       Date:  2003-07-23       Impact factor: 5.606

7.  The unfolded protein response affects readthrough of premature termination codons.

Authors:  Yifat S Oren; Michelle L McClure; Steven M Rowe; Eric J Sorscher; Assaf C Bester; Miriam Manor; Eitan Kerem; Joseph Rivlin; Fouad Zahdeh; Matthias Mann; Tamar Geiger; Batsheva Kerem
Journal:  EMBO Mol Med       Date:  2014-05       Impact factor: 12.137

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.